Download PDF
Pharmacopsychiatry 2014; 47(06): 202-209
DOI: 10.1055/s-0034-1385931
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Off-label Use of Memantine as Adjunctive Treatment in Schizophrenia: A Retrospective Case Series Study

J. P. John
1   Multimodal Brain Image Analysis Laboratory (MBIAL) NIMHANS, Bangalore, India
2   Department of Psychiatry, NIMHANS, Bangalore, India
3   Department of Clinical Neuroscience, NIMHANS, Bangalore, India
,
A. Lukose
1   Multimodal Brain Image Analysis Laboratory (MBIAL) NIMHANS, Bangalore, India
2   Department of Psychiatry, NIMHANS, Bangalore, India
,
S. Manjunath
1   Multimodal Brain Image Analysis Laboratory (MBIAL) NIMHANS, Bangalore, India
2   Department of Psychiatry, NIMHANS, Bangalore, India
› Author Affiliations
Further Information

Publication History

received 09 January 2014
revised 13 June 2014

accepted 15 July 2014

Publication Date:
28 August 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Memantine, an uncompetitive N-methyl D-aspartate receptor (NMDAR) open-channel blocker holds great promise for its potential clinical effectiveness as add-on therapy to on-going treatment with antipsychotics.

Methods: We report here the results of a chart review-based retrospective case series study that examined the effectiveness of off-label use of memantine in patients with schizophrenia when used as adjunctive therapy to standard neuroleptic therapy.

Results: 17 of the 26 patients, whose case files were reviewed using a study-specific proforma showed clinical improvement in positive and/or negative psychopathology as well as in cognitive and/or functional domains. The doses of on-going antipsychotic medications could be reduced in a sizeable number of responders. None of the subjects reported serious adverse events.

Discussion: Memantine holds great promise as adjunctive therapy for treatment of schizophrenia. Randomized controlled trials, wherein memantine is administered at adequate doses for an adequate period of time to ongoing antipsychotic treatment are required to confirm its efficacy in alleviating symptoms of schizophrenia.

Key words

augmentation therapy - add-on treatment - NMDAR open-channel blocker - glutamatergic hypothesis - neuroprotection
 

  • References

  • 1 Carlsson A, Waters N, Waters S et al. Network interactions in schizophrenia – therapeutic implications. Brain research Brain research reviews 2000; 31: 342-349
    CrossrefPubMedGoogle Scholar
  • 2 Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Molecular psychiatry 1999; 4: 418-428
    CrossrefPubMedGoogle Scholar
  • 3 Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. International review of neurobiology 2007; 78: 69-108
    PubMedGoogle Scholar
  • 4 Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain research reviews 2009; 60: 279-286
    CrossrefPubMedGoogle Scholar
  • 5 Lindsley CW, Shipe WD, Wolkenberg SE et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Current topics in medicinal chemistry 2006; 6: 771-785
    CrossrefPubMedGoogle Scholar
  • 6 Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of general psychiatry 1994; 51: 199-214
    CrossrefPubMedGoogle Scholar
  • 7 Malhotra AK, Pinals DA, Weingartner H et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 1996; 14: 301-307
    CrossrefPubMedGoogle Scholar
  • 8 Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nature reviews Drug discovery 2006; 5: 160-170
    CrossrefPubMedGoogle Scholar
  • 9 Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. Journal of neurochemistry 2006; 97: 1611-1626
    CrossrefPubMedGoogle Scholar
  • 10 Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx: the journal of the American Society for Experimental NeuroTherapeutics 2004; 1: 101-110
    PubMedGoogle Scholar
  • 11 Xia P, Chen HS, Zhang D et al. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. The Journal of neuroscience: the official journal of the Society for Neuroscience 2010; 30: 11246-11250
    CrossrefPubMedGoogle Scholar
  • 12 Rands GS. Memantine as a neuroprotective treatment in schizophrenia. The British journal of psychiatry: the journal of mental science 2005; 186: 77 author reply -8
    PubMedGoogle Scholar
  • 13 Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. The Annals of pharmacotherapy 2006; 40: 344-346
    CrossrefPubMedGoogle Scholar
  • 14 Thomas C, Carroll BT, Maley RT et al. Memantine and catatonic schizophrenia. The American journal of psychiatry 2005; 162: 626
    CrossrefPubMedGoogle Scholar
  • 15 Sleeper RB. Antipsychotic dose-sparing effect with addition of memantine. The Annals of pharmacotherapy 2005; 39: 1573-1576
    CrossrefPubMedGoogle Scholar
  • 16 Ponde MP, Novaes CM. Aripiprazole worsening positive symptoms and memantine reducing negative symptoms in a patient with paranoid schizophrenia. Rev Bras Psiquiatr 2007; 29: 92
    CrossrefPubMedGoogle Scholar
  • 17 Krivoy A, Weizman A, Laor L et al. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 2008; 18: 117-121
    CrossrefPubMedGoogle Scholar
  • 18 Rezaei F, Mohammad-Karimi M, Seddighi S et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology 2013; 33: 336-342
    CrossrefPubMedGoogle Scholar
  • 19 Lieberman JA, Papadakis K, Csernansky J et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2009; 34: 1322-1329
    CrossrefPubMedGoogle Scholar
  • 20 Lee JG, Lee SW, Lee BJ et al. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry investigation 2012; 9: 166-173
    CrossrefPubMedGoogle Scholar
  • 21 de Lucena D, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. The Journal of clinical psychiatry 2009; 70: 1416-1423
    CrossrefPubMedGoogle Scholar
  • 22 Matsuda Y, Kishi T, Iwata N. Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials. Journal of psychiatric research. 2013
    PubMedGoogle Scholar
  • 23 Cerullo MA, Adler CM, Strakowski SM et al. Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study. Schizophrenia research 2007; 97: 294-296
    CrossrefPubMedGoogle Scholar
  • 24 Surman CB, Hammerness PG, Petty C et al. A pilot open label prospective study of memantine monotherapy in adults with ADHD. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry 2013; 14: 291-298
    CrossrefPubMedGoogle Scholar
  • 25 Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Progress in neuro-psychopharmacology & biological psychiatry 2008; 32: 1362-1374
    CrossrefPubMedGoogle Scholar
  • 26 Sani G, Serra G, Kotzalidis GD et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS drugs 2012; 26: 663-690
    CrossrefPubMedGoogle Scholar
  • 27 Stafford RS. Regulating off-label drug use – rethinking the role of the FDA. The New England journal of medicine 2008; 358: 1427-1429
    CrossrefPubMedGoogle Scholar
  • 28 Mello MM, Studdert DM, Brennan TA. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. The New England journal of medicine 2009; 360: 1557-1566
    CrossrefPubMedGoogle Scholar
  • 29 Walton SM, Schumock GT, Lee KV et al. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 2008; 28: 1443-1452
    CrossrefPubMedGoogle Scholar
  • 30 Tsutsumi C, Uchida H, Suzuki T et al. The evolution of antipsychotic switch and polypharmacy in natural practice – a longitudinal perspective. Schizophrenia research 2011; 130: 40-46
    CrossrefPubMedGoogle Scholar
  • 31 Marcus MM, Jardemark K, Malmerfelt A et al. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence. Synapse 2012; 66: 277-290
    CrossrefPubMedGoogle Scholar
  • 32 Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 2012; 22: 165-182
    CrossrefPubMedGoogle Scholar
  • 33 Tiihonen J, Hallikainen T, Ryynanen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological psychiatry 2003; 54: 1241-1248
    CrossrefPubMedGoogle Scholar
  • 34 Gama CS, Antunes P, Moser C et al. Memantine as an adjunctive therapy for schizophrenia negative symptoms. Rev Bras Psiquiatr 2005; 27: 257-258
    PubMedGoogle Scholar
  • 35 John JP, Halahalli HN. Role of aberrant glutamatergic neurotransmission in psychiatric disorders: Focus on schizophrenia. In: Avasthi A. ed. Neurobiology of Psychiatric Disorders. Jaipur: Indian Psychiatric Society publication; 2010: 11-31
    Google Scholar
  • 36 Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Archives of neurology 2006; 63: 1372-1376
    CrossrefPubMedGoogle Scholar
  • 37 Uhlhaas PJ, Haenschel C, Nikolic D et al. The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophrenia bulletin 2008; 34: 927-943
    CrossrefPubMedGoogle Scholar
  • 38 Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues in clinical neuroscience 2011; 13: 155-172
    PubMedGoogle Scholar